Jiangsu Hengrui Medicine Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Jiangsu Hengrui Medicine Co., Ltd.
A Chinese court decision sheds light on how Chinese major Hengrui Medicine is seeking to reduce or avoid potential losses worth up to $27m following regulatory setbacks with the tubulin inhibitor plinabulin, in-licensed from BeyondSpring in 2021.
Simcere, Hengrui, and Zai Lab are among the first Chinese pharma firms to report various forms of impact from the gathering storm of a national anti-corruption campaign launched in July in the healthcare and pharma sectors.
Sintbilo (tafolecimab) is the first among four late-stage domestically developed PCSK9 Inhibitors to win the nod from China’s drug regulator. Despite lack of public reimbursement coverage, the drug could potentially unseat same-class rivals from Amgen and Sanofi/Regeneron.
As Beijing gets tougher in an all-out campaign to root out corruption and non-compliance in the pharma sector, more physician conferences are jeopardized and an increasing number of hospital presidents are placed under investigation. Meanwhile, one industry association issues new guidance for members.
- Generic Drugs
- Radiopharmaceuticals, Contrast Agents
- Large Molecule
- Other Names / Subsidiaries
- Atridia Pty Ltd
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Hengrui Therapeutics, Inc., Hengrui Pharmaceuticals, Fujian Shengdi Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Pharmaceutical Co., Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.